Cancers, Vol. 12, Pages 1861: NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs

Cancers, Vol. 12, Pages 1861: NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs Cancers doi: 10.3390/cancers12071861 Authors: Tyler Sheetz Joseph Mills Anna Tessari Megan Pawlikowski Ashley E. Braddom Tasha Posid Debra L. Zynger Cindy James Valerio Embrione Kareesma Parbhoo Claudia Foray Vincenzo Coppola Carlo M. Croce Dario Palmieri Prostate cancer (PCa) is the most frequently diagnosed cancer in men and second most common cause of cancer-related deaths in the United States. Androgen deprivation therapy (ADT) is only temporarily effective for advanced-stage PCa, as the disease inevitably progresses to castration-resistant prostate cancer (CRPC). The protein nucleolin (NCL) is overexpressed in several types of human tumors where it is also mislocalized to the cell surface. We previously reported the identification of a single-chain fragment variable (scFv) immuno-agent that is able to bind NCL on the surface of breast cancer cells and inhibit proliferation both in vitro and in vivo. In the present study, we evaluated whether NCL could be a valid therapeutic target for PCa, utilizing DU145, PC3 (CRPC), and LNCaP (androgen-sensitive) cell lines. First, we interrogated the publicly available databases and noted that higher NCL mRNA levels are associated with higher Gleason Scores as well as with recurrent and metastatic tumors. Then, using our anti-NCL scFv, we demonstrated that NCL is e...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research